Cargando…
阿法替尼一线治疗5例晚期肺腺癌患者的不良反应分析及相关文献回顾
BACKGROUND AND OBJECTIVE: Afatinib is an irreversible ErbB-family blocker with a clinical activity in non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations. The aim of this study is to assess the safety of afatinib in patients with advanced lung adenocarcinoma. METHODS: P...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000023/ https://www.ncbi.nlm.nih.gov/pubmed/24758910 http://dx.doi.org/10.3779/j.issn.1009-3419.2014.04.09 |